{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:58:45Z","timestamp":1785560325324,"version":"3.56.0"},"reference-count":38,"publisher":"Pharmaceutical Society of Japan","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,7,28]]},"DOI":"10.1248\/bpb.b26-00139","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:11:38Z","timestamp":1785190298000},"page":"1182-1193","source":"Crossref","is-referenced-by-count":0,"title":["Successive and Isoform-Specific Remodeling of Hepatic Drug-Metabolizing Enzymes during Metabolic Dysfunction-Associated Steatotic Liver Disease\/Metabolic Dysfunction-Associated Steatohepatitis Progression"],"prefix":"10.1248","volume":"49","author":[{"given":"Yusuke","family":"Ando","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pathology, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1\u20131 Keyakidai, Sakado, Saitama 350\u20130295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Arai","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pathology, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1\u20131 Keyakidai, Sakado, Saitama 350\u20130295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Tsukui","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pathology, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1\u20131 Keyakidai, Sakado, Saitama 350\u20130295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pathology, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1\u20131 Keyakidai, Sakado, Saitama 350\u20130295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mako","family":"Okabe","sequence":"additional","affiliation":[{"name":"Laboratory of Physical Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1\u20131 Keyakidai, Sakado, Saitama 350\u20130295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Egawa","sequence":"additional","affiliation":[{"name":"Laboratory of Physical Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1\u20131 Keyakidai, Sakado, Saitama 350\u20130295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kitaoka","sequence":"additional","affiliation":[{"name":"Laboratory of Physical Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1\u20131 Keyakidai, Sakado, Saitama 350\u20130295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. <i>Hepatology<\/i>, <b>64<\/b>, 73\u201384 (2016).","DOI":"10.1002\/hep.28431"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Estes C, Anstee QM, Arias-Loste MT, <i>et al<\/i>. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. <i>J. Hepatol.<\/i>, <b>69<\/b>, 896\u2013904 (2018).","DOI":"10.1016\/j.jhep.2018.05.036"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. <i>Nat. Rev. Gastroenterol. Hepatol.<\/i>, <b>15<\/b>, 11\u201320 (2018).","DOI":"10.1038\/nrgastro.2017.109"},{"key":"4","unstructured":"4) Rinella ME, Lazarus JV, Ratziu V, <i>et al<\/i>. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. <i>Ann. Hepatol.<\/i>, <b>29<\/b>, 101133 (2024)."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. <i>Nat. Med.<\/i>, <b>24<\/b>, 908\u2013922 (2018).","DOI":"10.1038\/s41591-018-0104-9"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. <i>Hepatology<\/i>, <b>52<\/b>, 1836\u20131846 (2010).","DOI":"10.1002\/hep.24001"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. <i>Hepatology<\/i>, <b>49<\/b>, 306\u2013317 (2009).","DOI":"10.1002\/hep.22603"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD)\u2014pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. <i>Drug Metab. Rev.<\/i>, <b>49<\/b>, 197\u2013211 (2017).","DOI":"10.1080\/03602532.2017.1293683"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Guengerich FP. Cytochrome P450 and chemical toxicology. <i>Chem. Res. Toxicol.<\/i>, <b>21<\/b>, 70\u201383 (2008).","DOI":"10.1021\/tx700079z"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Rendic S, Guengerich FP. Survey of human oxidoreductases and cytochrome P450 enzymes involved in the metabolism of xenobiotic and natural chemicals. <i>Chem. Res. Toxicol.<\/i>, <b>28<\/b>, 38\u201342 (2015).","DOI":"10.1021\/tx500444e"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. <i>Annu. Rev. Pharmacol. Toxicol.<\/i>, <b>40<\/b>, 581\u2013616 (2000).","DOI":"10.1146\/annurev.pharmtox.40.1.581"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL, McManus ME. Human sulfotransferases and their role in chemical metabolism. <i>Toxicol. Sci.<\/i>, <b>90<\/b>, 5\u201322 (2006).","DOI":"10.1093\/toxsci\/kfj061"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. <i>Pharmacol. Ther.<\/i>, <b>138<\/b>, 103\u2013141 (2013).","DOI":"10.1016\/j.pharmthera.2012.12.007"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, Cherrington NJ. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. <i>Drug Metab. Dispos.<\/i>, <b>37<\/b>, 2087\u20132094 (2009).","DOI":"10.1124\/dmd.109.027466"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Hardwick RN, Ferreira DW, More VR, Lake AD, Lu Z, Manautou JE, Slitt AL, Cherrington NJ. Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease. <i>Drug Metab. Dispos.<\/i>, <b>41<\/b>, 554\u2013561 (2013).","DOI":"10.1124\/dmd.112.048439"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. <i>Clin. Pharmacol. Ther.<\/i>, <b>85<\/b>, 434\u2013438 (2009).","DOI":"10.1038\/clpt.2008.302"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, Nebert DW. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. <i>Pharmacogenet. Genomics<\/i>, <b>15<\/b>, 677\u2013685 (2005).","DOI":"10.1097\/01.fpc.0000173483.13689.56"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. <i>Int. J. Biochem. Cell Biol.<\/i>, <b>45<\/b>, 1121\u20131132 (2013).","DOI":"10.1016\/j.biocel.2013.02.019"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Tolson AH, Wang H. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. <i>Adv. Drug Deliv. Rev.<\/i>, <b>62<\/b>, 1238\u20131249 (2010).","DOI":"10.1016\/j.addr.2010.08.006"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Matsumoto M, Hada N, Sakamaki Y, Uno A, Shiga T, Tanaka C, Ito T, Katsume A, Sudoh M. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. <i>Int. J. Exp. Pathol.<\/i>, <b>94<\/b>, 93\u2013103 (2013).","DOI":"10.1111\/iep.12008"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Masaki S, Hashimoto Y, Kunisho S, Kimoto A, Kitadai Y. Fatty change of the liver microenvironment influences the metastatic potential of colorectal cancer. <i>Int. J. Exp. Pathol.<\/i>, <b>101<\/b>, 162\u2013170 (2020).","DOI":"10.1111\/iep.12371"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Staten NR, Welsh EA, Sidik K, McDonald SA, Dufield DR, Maqsodi B, Ma Y, McMaster GK, Mathews RW, Arch RH, Masferrer JL, Souberbielle BE. Multiplex transcriptional analysis of paraffin-embedded liver needle biopsy from patients with liver fibrosis. <i>Fibrogenesis Tissue Repair<\/i>, <b>5<\/b>, 21 (2012).","DOI":"10.1186\/1755-1536-5-21"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Gan C, Yaqoob U, Lu J, Xie M, Anwar A, Jalan-Sakrikar N, Jerez S, Sehrawat TS, Navarro-Corcuera A, Kostallari E, Habash NW, Cao S, Shah VH. Liver sinusoidal endothelial cells contribute to portal hypertension through collagen type IV-driven sinusoidal remodeling. <i>JCI Insight<\/i>, <b>9<\/b>, e174775 (2024).","DOI":"10.1172\/jci.insight.174775"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. <i>Lancet<\/i>, <b>397<\/b>, 2212\u20132224 (2021).","DOI":"10.1016\/S0140-6736(20)32511-3"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Morgan ET. Regulation of cytochrome P450 by inflammatory mediators: why and how? Drug Metab. <i>Dispos.<\/i>, <b>29<\/b>, 207\u2013212 (2001).","DOI":"10.1016\/S0300-483X(02)00283-4"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. <i>Annu. Rev. Pharmacol. Toxicol.<\/i>, <b>43<\/b>, 309\u2013334 (2003).","DOI":"10.1146\/annurev.pharmtox.43.100901.135828"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Bock KW. From TCDD-mediated toxicity to searches of physiologic AHR functions. <i>Biochem. Pharmacol.<\/i>, <b>155<\/b>, 419\u2013424 (2018).","DOI":"10.1016\/j.bcp.2018.07.032"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. <i>Expert Opin. Drug Metab. Toxicol.<\/i>, <b>2<\/b>, 875\u2013894 (2006).","DOI":"10.1517\/17425255.2.6.875"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Scheer N, Kapelyukh Y, Chatham L, Rode A, Buechel S, Wolf CR. Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines. <i>Mol. Pharmacol.<\/i>, <b>82<\/b>, 1022\u20131029 (2012).","DOI":"10.1124\/mol.112.080036"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Kitaoka S, Hatogai J, Ochiai W, Sugiyama K. Zonation of the drug-metabolizing enzyme cytochrome P450 3A in infant mice begins in pre-weaning period. <i>J. Toxicol. Sci.<\/i>, <b>43<\/b>, 223\u2013227 (2018).","DOI":"10.2131\/jts.43.223"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Fujino C, Sanoh S, Katsura T. Variation in expression of cytochrome P450 3A isoforms and toxicological effects: endo- and exogenous substances as regulatory factors and substrates. <i>Biol. Pharm. Bull.<\/i>, <b>44<\/b>, 1617\u20131634 (2021).","DOI":"10.1248\/bpb.b21-00332"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Okamura M, Shizu R, Hosaka T, Sasaki T, Yoshinari K. Possible involvement of the competition for the transcriptional coactivator glucocorticoid receptor-interacting protein 1 in the inflammatory signal-dependent suppression of PXR-mediated CYP3A induction in vitro. <i>Drug Metab. Pharmacokinet.<\/i>, <b>34<\/b>, 272\u2013279 (2019).","DOI":"10.1016\/j.dmpk.2019.04.005"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. <i>J. Clin. Invest.<\/i>, <b>101<\/b>, 847\u2013854 (1998).","DOI":"10.1172\/JCI915"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Mackenzie PI, Hu DG, Gardner-Stephen DA. The regulation of UDP-glucuronosyltransferase genes by tissue-specific and ligand-activated transcription factors. <i>Drug Metab. Rev.<\/i>, <b>42<\/b>, 99\u2013109 (2010).","DOI":"10.3109\/03602530903209544"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Falany CN, Xie X, Wang J, Ferrer J, Falany JL. Molecular cloning and expression of novel sulphotransferase-like cDNAs from human and rat brain. <i>Biochem. J.<\/i>, <b>346<\/b>, 857\u2013864 (2000).","DOI":"10.1042\/bj3460857"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Brettrager EJ, Meehan AW, Falany CN, van Waardenburg R. Sulfotransferase 4A1 activity facilitates sulfate-dependent cellular protection to oxidative stress. <i>Sci. Rep.<\/i>, <b>12<\/b>, 1625 (2022).","DOI":"10.1038\/s41598-022-05582-4"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Woolsey SJ, Mansell SE, Kim RB, Tirona RG, Beaton MD. CYP3A activity and expression in nonalcoholic fatty liver disease. <i>Drug Metab. Dispos.<\/i>, <b>43<\/b>, 1484\u20131490 (2015).","DOI":"10.1124\/dmd.115.065979"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. <i>Nat. Rev. Genet.<\/i>, <b>13<\/b>, 227\u2013232 (2012).","DOI":"10.1038\/nrg3185"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/7\/49_b26-00139\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:23:47Z","timestamp":1785558227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/7\/49_b26-00139\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00139","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"b26-00139"}}